Conventional Clipping Versus Punching Closure

Launched by NINGBO NO. 1 HOSPITAL · Apr 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of closing wounds that occur after a procedure called endoscopic submucosal dissection (ESD), which is used to treat early tumors in the digestive tract. The trial compares traditional clip closure, a common method, to a newer technique called punch closure, which may be better for larger or harder-to-reach wounds. Researchers want to find out if punch closure is safe and effective, especially since early studies suggest it might be, but more evidence is needed.

To participate in this trial, individuals need to be between 18 and 75 years old and must agree to take part by signing a consent form. They should be undergoing ESD wound closure at the First Affiliated Hospital of Ningbo University between April 2024 and December 2025. However, some people may not be eligible, such as those with certain serious health conditions or those who are pregnant. Participants can expect to contribute to important research that could improve the way doctors close wounds after ESD, potentially leading to better outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing gastrointestinal ESD wound closure in the First Affiliated Hospital of Ningbo University from April 20, 2024 to December 31, 2025; 2. Age 18-75 years old; 3. Patients who voluntarily agreed to participate in this study and signed informed consent.
• Exclusion Criteria:
• • 1. Persons under the age of 18 2. Unwilling or unable to provide informed consent 3. Treatment or radiotherapy for malignant diseases, severe chronic heart or lung diseases, coronary or cerebrovascular events requiring hospitalization within the last 3 months 4.. Severe abdominal pain, bloating, nausea and other abdominal symptoms 5.. Patients with lifelong anticoagulant therapy or severe bleeding disorders, and patients who have recently taken anticoagulant or antiplatelet drugs 6. Pregnant or lactating 7. Patients with aggressive lesions and recurrent or residual tumors